Navigation Links
King Announces Commercial Availability of EMBEDA(TM)
Date:9/21/2009

e by competitively binding to opioid receptors. Opioid antagonists are commonly used to reverse the effects of opioids in overdose emergencies and for the treatment of alcohol dependence.

Will Rowe, CEO of the American Pain Foundation, stated, "Effective pain management begins by removing barriers and helping patients manage their pain. When used responsibly and monitored regularly, these new technologies may help ease concerns prescribers may have when recommending current standard-of-care opioid treatments-allowing more pain patients to get the care they need."

In order to ensure that the benefits of EMBEDA(TM) outweigh the potential risks of EMBEDA(TM), King has implemented a Risk Evaluation and Mitigation Strategy (REMS) in response to a requirement of the FDA. The goals of this REMS are to inform patients and providers about the potential for abuse, misuse, overdose, and addiction of EMBEDA(TM) and about the safe use of EMBEDA(TM). The REMS program for EMBEDA(TM) also provides education on additional areas including, but not limited to, individualizing dosage, proper patient selection, and warnings and precautions. Side effect profiles should be considered when prescribing EMBEDA(TM), as they are similar to other opioid analgesics. EMBEDA(TM) is meant to be swallowed whole or opened and the contents of the capsules sprinkled on applesauce. The pellets in the capsules are not to be crushed, dissolved, or chewed due to the risk of rapid release and absorption of a potentially fatal dose of morphine.

Important Safety Information: Black Box Warning

--------------------------------------------------------------------------

WARNING: EMBEDA(TM) (morphine sulfate and naltrexone hydrochloride) Extended Release Capsules contain morphine, an opioid agonist and a Schedule II controlled substance with an abuse liability similar to other opioid agonists. EMBEDA(TM) can be abused in a manne
'/>"/>

SOURCE King Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine news :

1. DOR BioPharma Announces $9.4 Million NIH Grant Award to Develop Thermostable and Rapidly Acting Vaccines
2. ATS Medical Announces Implant Milestone for the ATS 3f Aortic Bioprosthesis Achieved at Columbia University Medical Center
3. PDL BioPharma Announces Conversion Rate Adjustment for Its 2.75% Convertible Subordinated Notes Due August 16, 2023
4. Aptilon Announces Acquisition of Direct Medical Data, LLC and BLM Incorporated and Concurrent Private Placements
5. International Isotopes Inc. Announces Successful Completion of a Private Placement
6. HLTH Corporation Announces Agreement to Sell Porex Unit to Aurora Capital Group for $142 Million
7. avVaa World Health Care Products, Inc. Announces Updated Financials
8. China Medical Technologies Announces US$30 Million Share Repurchase Program
9. Exiqon Announces Achievement of Primary Milestones in RNAi Project for Tacere Therapeutics
10. 4 Stair Lifts Announces Grand Opening of Online Store
11. SXC Health Solutions announces pricing of upsized public offering of common shares
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... Ashburn, Virginia (PRWEB) July 11, 2014 ASHBURN ... 367 took effect, which allows individuals with an intellectual disability ... back of their licenses and ID cards to alert law ... with a condition. The idea was inspired by a ... proactive in protecting her 9 year old autistic son, JP. ...
(Date:7/10/2014)... consuming a supplement of omega 3 fatty acids had ... fats and omega 6 fatty acids, according to Duke ... Annals of the Rheumatic Diseases (10.1136/annrheumdis-2014-205601) on July ... just obesity may contribute to worsening osteoarthritis. , ... significant role than mechanical factors in the link between ...
(Date:7/10/2014)... Thousands of researchers from more than ... 13-17 to reveal the latest study results, theories ... in dementia science. The Alzheimer’s Association International Conference ... kind. , As part of the Alzheimer’s Association’s ... generating new knowledge about dementia and fostering a ...
(Date:7/10/2014)... City, NY (PRWEB) July 10, 2014 ... life sciences industry, has launched a new website. ... as well as increased access to the firm’s thought ... cbpartners.com provides an ideal platform to showcase our insights, ... access issues,” says CBPartners’ Chief Executive Officer, Cyrus Chowdhury. ...
(Date:7/10/2014)... York (PRWEB) July 10, 2014 ... to protecting the rights of victims injured by ... brought a lawsuit over allegations that the woman’s ... by a power morcellator used during a routine ... filed against Richard Wolf Medical Instruments Corporation over ...
Breaking Medicine News(10 mins):Health News:Recent Special “Autism” Code on Virginia Driver’s Licenses and ID Cards Goes into Law: Helpful or Discriminatory for Individuals on the Autistic Spectrum? 2Health News:Recent Special “Autism” Code on Virginia Driver’s Licenses and ID Cards Goes into Law: Helpful or Discriminatory for Individuals on the Autistic Spectrum? 3Health News:Omega 3 fatty acids lessen severity of osteoarthritis in mice 2Health News:CBPartners Announces New Website 2Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 2Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 3Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 4Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 5
... Parents really need to stop their kids from becoming mini-couch ... dont get regular exercise are at risk of chronic ... of their study, researchers from the British Heart Foundation examined ... secondary schools in Leicester. ,They found that half ...
... conducted by a team of researchers led by Dr Peter ... ,As part of the study, researchers analysed schoolchildren who ... ,Researchers asked their parents about their kids fruit ... ,The study found that although there was no connection between ...
... of climbers have collected half a tonne of junk littered ... Monday . ,The garbage was mostly left behind ... kilos of essential items are hauled up the mountain in ... Ken Noguchi told reporters here that the expedition collected garbage ...
... exercise appears to modestly increase levels of high-density ... meta-analysis study in the issue of Archives of ... high-density lipoprotein cholesterol (HDL-C) is an independent risk ... death worldwide, according to background information in the ...
... Substituting soy nuts for other protein sources in a ... women , and also may reduce cholesterol levels in ... in the issue of Archives of Internal Medicine. ... pressure (hypertension) affects approximately 50 million Americans and 1 ...
... studying the addition of sugars to proteins ... system of insects, Karen Palter, researcher of Temple ... better understand neurodegenerative diseases in humans. Currently, her ... exploring the glycosylation process that could eventually play ...
Cached Medicine News:Health News:Apple Juice may Help to Keep Childhood Asthma at Bay 2Health News:Regular Exercise may Slightly Increase HDL Levels 2Health News:Soy Nuts may Improve Blood Pressure, Cholesterol Levels in Women 2Health News:Nervous Systems of Insects may Offer Clues on Neurodegenerative Diseases 2Health News:Nervous Systems of Insects may Offer Clues on Neurodegenerative Diseases 3
(Date:1/15/2014)... 2014  Humberto C. Antunes,  Galderma  worldwide CEO, will receive ... Journal of Drugs in Dermatology (JDD) at the ... event is January 17-20, 2014, at the Omni Orlando Resort at ... The ODAC is a distinguished event that delivers ...
(Date:1/15/2014)... Fla. , Jan. 15, 2014  In an unprecedented effort to ... TB in ambulances and other transport vehicles, an advanced and portable ... rescue personnel for the first time. In order ... with these deadly pathogens, West Palm Beach ...
(Date:1/15/2014)... , Jan. 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ... developing its Symphony® CGM System as a non-invasive, wireless ... F. Doman , Executive Chairman and Interim CEO of ... Markets, Tenth Annual Equity Conference. Mr. ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Superbugs No Longer Ride In Rescue Vehicles 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... 2007 - Accentia,Biopharmaceuticals, Inc. (NASDAQ: ABPI) announced ... Conference that its interim,analysis of the blinded ... the,Fast-Tracked Phase 3 clinical study of SinuNase(TM), ... in,resolution of one or both of the ...
... WIRE)--Jun 28, 2007 - CombinatoRx,Incorporated (NASDAQ: CRXX) ... placebo-controlled clinical trial of,CRx-150 in patients with ... a disease-modifying anti-rheumatic drug,(DMARD) to placebo plus ... the preliminary analysis of this trial, CRx-150 ...
Cached Medicine Technology:Accentia Biopharmaceuticals Announces Favorable Interim Blinded,Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial,for Chronic Sinusitis 2Accentia Biopharmaceuticals Announces Favorable Interim Blinded,Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial,for Chronic Sinusitis 3Accentia Biopharmaceuticals Announces Favorable Interim Blinded,Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial,for Chronic Sinusitis 4CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and,Pain, but Not CRP 2CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and,Pain, but Not CRP 3CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and,Pain, but Not CRP 4CombinatoRx Product Candidate CRx-150 Shows Activity on DAS28 and,Pain, but Not CRP 5
... Combining the therapeutic benefits of controlled compression ... swelling, and pain. The anatomically designed cuff ... Cryo/Cuffs can be ordered as a single ... tube assembly and insulation disk). The Cooler ...
... designed to comfortably restrict motion of ... motion of the fingers and wrist. ... splint may be trimmed using cast ... gun. One cotton stockinet is included ...
... Cronin, Inc. is a ... Footwear, Orthopedic Softgoods, and ... Our products are of ... available in the USA ...
... Cronin, Inc. is a ... Footwear, Orthopedic Softgoods, and ... Our products are of ... available in the USA ...
Medicine Products: